LONDON--(BUSINESS WIRE)--The global methyl ethyl ketone (MEK) market is expected to grow at a CAGR of close to 5% during the period 2018-2022, according to a new market research study by Technavio.
GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback